Remove Dermatitis Remove Dermatology Remove Treatments
article thumbnail

Dupilumab for Atopic Dermatitis: 7 Years Later

Dermatology Times

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

article thumbnail

Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms

Dermatology Times

Dr Alexandra Golant discusses managing multiple conditions in a 17-year-old African American waitress, highlighting the complexities of treating moderate-to-severe atopic dermatitis alongside severe acne and oral contraceptives. She also addresses potential drug interactions, focusing on the safety of dupilumab in systemic treatment.

article thumbnail

Unraveling the Advancements in Seborrheic Dermatitis Treatment

Dermatology Times

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

article thumbnail

Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

Dermatology Times

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

article thumbnail

Understanding The Heterogenous Nature of Atopic Dermatitis

Dermatology Times

Mark Lebwohl, MD, emphasizes the importance of considering various factors, including severity of itch and interference with sleep, when determining treatments for patients with atopic dermatitis, even with presentation may not include typical symptoms.

article thumbnail

Arcutis’ Zoryve Foam Is Now Available for Seb Derm Treatment in the U.S.

The Dermatology Digest

s ZORYVE topical foam, 0.3%, is now officially available for the treatment of seborrheic dermatitis. Food and Drug Administration (FDA) approved ZORYVE foam for the treatment of seborrheic dermatitis in individuals 9 years of age and older on December 15, 2023. appeared first on The Dermatology Digest.

article thumbnail

New Ladder Helps Guide Choice of Non-steroidal Treatments in AD

The Dermatology Digest

A newly developed therapeutic ladder can help guide dermatologists and patients on the use of nonsteroidal treatment options for atopic dermatitis (AD). Nonsteroidal treatment options for AD have rapidly expanded in recent years with the development of phosphodiesterase-4 inhibitors, biologics, and Janus kinase (JAK) inhibitors.